CAR T cells targeting CD19 and B-cell maturation antigen (BCMA) have successfully treated hematological malignancies such as relapsed or refractory acute lymphoblastic leukemia, large B cell lymphoma, and multiple myeloma (1, 2). Here, TNFRSF17 is linked to plasma cell myeloma.